Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

Group 1 - Halozyme Therapeutics announced that Bristol Myers Squibb received European Commission approval for a new subcutaneous formulation of Opdivo® (nivolumab) for multiple adult solid tumors [1][2] - The subcutaneous injection of Opdivo® can be administered in 3 to 5 minutes, providing a more convenient option for cancer patients [2] - The approval is valid across all 27 EU member states, as well as Iceland, Liechtenstein, and Norway [3] Group 2 - The positive decision from the European Commission is supported by results from the Phase 3 CheckMate -67T trial [2] - Halozyme's ENHANZE® technology, which facilitates subcutaneous drug delivery, has been licensed to several leading pharmaceutical companies [4] - Halozyme has impacted over one million patients through its commercialized products and aims to improve patient experiences with rapid subcutaneous delivery [4]